All sponsors

R-Pharm International, LLC

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS1
Open R-Pharm International, LLC on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
RPH-104
NCT05092776
P2Active, not recruitingFamilial Mediterranean Fever; FMF842025-01
RPH-104
NCT05673902
P3Active, not recruitingIdiopathic Recurrent Pericarditis172026-01
Olokizumab
NCT07670546
P3Active, not recruitingPolymyalgia Rheumatica1252026-04-10
RS-113, 160 mg
NCT07553988
P2Active, not recruitingMetastatic Castration-resistant Prostate Cancer1202026-05-14
OKZ q4w
NCT07517575
P2RecruitingJuvenile Idiopathic Arthritis712026-09
Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
NCT06440746
P2/3RecruitingLung Diseases, Interstitial1382027-04-09 (+10 mo)
Goflikicept
NCT07625384
P3Not yet recruitingStill Disease522027-12-14
RPH-104
NCT05190991
P2RecruitingFamilial Mediterranean Fever; FMF602028-12 (+71 mo)